Stocktoria
Rein Therapeutics, Inc. RNTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-06-29
Rein Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $11.0M | $14.2M | $4.0M | $18.0M | $17.0M |
| Operating income | -$50.6M | -$65.1M | -$16.3M | -$27.6M | -$26.6M |
| Income tax | -$712,000 | -$1.5M | $0 | $0 | $0 |
| Net income | -$49.9M | -$62.9M | -$15.7M | -$27.3M | -$26.2M |
| EPS (diluted) | $-1.96 | $-3.51 | $-3.42 | $-6.02 | $-5.89 |
| Operating cash flow | -$19.4M | -$22.3M | -$19.8M | -$24.9M | -$23.8M |
| Free cash flow | — | — | — | — | -$23.9M |
| Cash & equivalents | $3.2M | $12.9M | $17.3M | $5.2M | $3.6M |
| Total assets | $24.2M | $62.2M | $106.0M | $22.0M | $48.5M |
| Total liabilities | $7.2M | $7.8M | $7.7M | $3.4M | $4.6M |
| Shareholders' equity | $16.9M | $54.4M | $98.3M | $18.6M | $43.9M |
Source: SEC EDGAR filings · CIK 0001420565 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.